Friday, 25 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 24, 2026

BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs

View original at globenewswire.com
BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfoli…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BioNTech currently has 16 clinical trials running for various lung cancer subtypes and treatment lines, including four registrational Phase 3 trials and five trials with innovative combination approaches

    60% confidence

  • The data presented at ELCC 2026 demonstrate the potential of BioNTech's late-stage lung cancer portfolio, with updates on Pumitamig and Gotistobart as well as first clinical data for HER3-targeted ADC candidate BNT326/YL202, driving forward differentiated treatment approaches for various lung cancer stages

    60% confidence

  • Gotistobart showed a clinically relevant overall survival benefit with a 54% reduction in mortality risk compared to current standard of care in second-line and later treatment of squamous lung cancer

    60% confidence

  • Pumitamig data support the currently ongoing registrational Phase 3 trial ROSETTA Lung-01 for first-line treatment of extensive-stage small cell lung cancer

    60% confidence

  • BioNTech's goal is to offer patients with lung cancer innovative treatment options that aim to enable significant long-term benefit across all disease stages

    60% confidence

Data points we hold from this source

BioNTech SE · combination therapy trials5 trials
BioNTech SE · active lung cancer trials16 trials
BioNTech SE · phase 3 trials4 trials
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs — Source | Via News | ViaNews EU